title: RE: A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer.
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China (HWz, XLp); State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangzhou, Guangdong, P. R. China (HWz, XLp).
authors.forename: He
authors.initials: H
authors.lastname: Wen-zhuo
authors.affiliation: VIP Region, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China (HWz, XLp); State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangzhou, Guangdong, P. R. China (HWz, XLp). xialiangping@163.com.
authors.forename: Xia
authors.initials: X
authors.lastname: Liang-ping
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D018631:ras Proteins / Q000235:genetics*
chemical_list: D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D017526:Receptor, IGF Type 1; D018631:ras Proteins